CALGARY, Alberta, May 03, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the
“Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated its first patient under its continuing
Phase II Clinical Trial for critical limb ischemia (“CLI”). The first patient was treated at the Vancouver Coastal Health
Research Institute (“VCHRI”), a world leader in translational health research for new therapies, led by the principal investigator,
Dr. York N. Hsiang, MB ChB MHSc FRCSC.
As previously announced, the VCHRI is the Company’s first Canadian trial site that is actively onboarding
patients for the continuing trial. The Company has approximately 14 additional clinical trial sites located in Canada and the
United States that are in various stages of the on-boarding process including 5 sites that have approved the Company’s clinical
trial agreement pending final review board or budget approvals.
The ongoing Phase II clinical trial investigates the safety and efficacy of the Company’s lead product,
ACP-01. The Company’s patented process results in producing specific stem cells that have the ability to support the
generation of new blood vessels to combat the life-threatening complications of CLI. The stem cells are raised and expanded from
the patient’s blood and then re-injected into the diseased tissue. The results of the current clinical trial will determine
whether the curative effects seen in Phase I trials of ACP-01 will be equally strong in a larger and more varied patient group.
“We are thrilled to be participating in the clinical trial of this potentially game-changing therapy for
patients with CLI. This trial is an important step forward in technology for treating vascular diseases such as CLI.” said
Dr. Hsiang.
“This first patient treatment is a critical milestone for Hemostemix as we continue to advance ACP-01 as a
potentially revolutionary treatment for CLI and other diseases,” states Kyle Makofka, Chief Executive Officer and President of
Hemostemix. “The millions of patients who suffer from CLI have limited treatment options outside of amputation, so the benefits of
ACP-01 therapy could be a vital treatment option resulting in bettering lives.”
The Company is also pleased to announce the appointment of Kristin Gulka, CPA, CA as the Company's Chief
Financial Officer effective May 1, 2018, subject to regulatory approval.
Ms. Gulka has over 10 years of financial, accounting and management experience for public and private companies.
For the past 7 years, she worked in a number of roles, including controller and corporate controller, within the finance
department at Ferus, a Calgary-based energy service and liquid natural gas company with operations throughout North America.
Prior thereto, she was interim controller at SemBioSys Genetics Inc., a biotechnology company conducting phase I and II clinical
trials. Kristin was named to the National Honour Roll when she completed her Uniform Final Exam (now known as the Common
Final Examination) and went on to achieve her Chartered Professional Accountant (CA) designation. She also obtained a
Bachelor of Commerce (Accounting) degree from the University of Calgary.
The Company also announces the departure of David Berman from the position of Chief Financial Officer, but he
will remain with the Company on a temporary consulting basis. We thank David for his contributions to the Company and wish
him well with his future endeavors.
"We are delighted to have Kristin Gulka join Hemostemix in the capacity of CFO. Her extensive experience in
accounting and strong financial oversight make her a welcome member of the executive team, as we move forward with Hemostemix's
global initiatives," said Kyle Makofka.
ABOUT HEMOSTEMIX INC.
Hemostemix is a publicly traded clinical-stage biotechnology company that develops and commercializes innovative
blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage
biotech company to test a stem-cell therapy in an international, multicenter, Phase II clinical trial for patients with critical
limb ischemia (“CLI”), a severe form of peripheral artery disease (“PAD”) caused by reduced blood flow to the legs. The Phase II
trial targets a participant’s diseased tissue with proprietary cells grown from his or her blood that can support the formation of
new blood vessels. The Company’s intellectual property portfolio includes over 50 patents issued or pending throughout the
world. Hemostemix has a manufacturing contract with Aspire Health Science, LLP (“Aspire”), for the production of ACP-01 and
for research and development purposes at Aspire’s Orlando, Florida, facility. Building towards commercialization, Hemostemix
has also licensed the use, sale and import of ACP-01 for certain indications to Aspire in certain jurisdictions. The Company is
continuing research and development of its lead product, ACP-01 with other applications, including cardiovascular, neurological and
vascular indications.
For more information, please visit www.hemostemix.com or email office@hemostemix.com.
Contact:
Kyle Makofka, President and CEO
Suite 1049, 150 – 9th Avenue S.W.
Calgary, Alberta T2P 3H9
Phone: (403) 506-3373
E-Mail: kmakofka@hemostemix.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under
the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,”
“intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,”
“may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are
based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially
from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of
Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and
unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but
are not limited to, the Company’s stage of development, future clinical trial results, long-term capital requirements and future
ability to fund operations, future developments in the Company’s markets and the markets in which it expects to compete, risks
associated with its strategic alliances and the impact of entering new markets on the Company’s operations. Each factor should be
considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly
disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information,
future events, or otherwise.
